chidamide + tislelizumab + capecitabine + oxaliplatin

This is a combination regimen of four drugs used in oncology, primarily investigated for the treatment of advanced or metastatic solid tumors, especially gastrointestinal cancers. The regimen includes: - **Chidamide**: A histone deacetylase (HDAC) inhibitor that modulates gene expression and induces apoptosis in cancer cells. - **Tislelizumab**: A humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Capecitabine**: An oral prodrug of 5-fluorouracil (5-FU), which is converted to its active form within tumor cells, inhibiting DNA synthesis and leading to cell death[1][2][4]. - **Oxaliplatin**: A platinum-based chemotherapy agent that forms DNA crosslinks, disrupting DNA replication and transcription[1][2][4]. The combination leverages both cytotoxic chemotherapy and immunotherapy approaches. Capecitabine plus oxaliplatin is a well-established backbone for colorectal cancer treatment; adding chidamide may provide epigenetic modulation, while tislelizumab enhances immune-mediated tumor killing.